Product Details
| Product Name:
Tecadenoson |
CAS No.:
204512-90-3 |
| Purity:
99.76% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | Tecadenoson |
| Description | Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist. |
| In vitro | Tecadenoson is approximately 5 fold more potent to prolong the stimulus-to-His bundle (S-H interval), a measure of slowing AV nodal conduction (EC50=41?nM) than to increase coronary conductance (EC50=200?nM) in the atrial-paced isolated heart. Tecadenoson shortens atrial (EC50=73?nM) but not the ventricular monophasic action potentials (MAP). At concentrations of Tecadenoson (40?nM) and diltiazem (1?μM) that induces equal prolongation of S-H interval (～10?ms), diltiazem, but not Tecadenoson, significantly decreases left ventricular developed pressure (LVP) and markedly increases coronary conductance [1]. |
| In vivo | Intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval In atrial-paced anaesthetized guinea-pigs. Tecadenoson (2, 5, 20 μg/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson (50 μg/kg) treatment induces a significant bradycardia (50% decrease in heart rate at 25 min) [1][2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 155 mg/mL (459.49 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (14.82 mM), Sonication is recommended.
|
| Keywords | Tecadenoson | P1 receptor | Inhibitor | inhibit | CVT510 | CVT 510 | AdenosineReceptor | Adenosine Receptor | A1 adenosine receptor | A1 |
| Inhibitors Related | Xanthine | Theophylline monohydrate | Diphylline | Adenosine monophosphate | Acefylline | Sulcatone | Adenosine 5'-monophosphate monohydrate | Inosine | Theobromine | Adenosine 5'-monophosphate disodium salt | Theophylline | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States